✦ LIBER ✦

Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib

✍ Scribed by Fernández de Larrea, Carlos; Martín-Antonio, Beatriz; Cibeira, Maria Teresa; Navarro, Alfons; Tovar, Natalia; Díaz, Tania; Rosiñol, Laura; Monzó, Mariano; Urbano-Ispizua, Alvaro; Bladé, Joan

Book ID: 120249257
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 309 KB
Volume: 37
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2013.01.013

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Impact of prior therapies on the relativ

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma

✍ Dan T. Vogl; Edward A. Stadtmauer; Paul G. Richardson; Pieter Sonneveld; Michael 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB

Impact on response and survival of DNA r

Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide

✍ María Teresa Cibeira; Carlos Fernández de Larrea; Alfons Navarro; Tania Díaz; Do 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 332 KB

The potential benefits of participating

The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib

✍ Paul G. Richardson; Jacob P. Laubach; Robert L. Schlossman; Irene M. Ghobrial; K 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

High response rate to bortezomib with or

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

✍ Joseph R. Mikhael; Andrew R. Belch; H. Miles Prince; Maria Nambo Lucio; Angelo M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 272 KB

An open-label, single-arm, phase 2 study

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

✍ Ravi Vij; David S. Siegel; Sundar Jagannath; Andrzej J. Jakubowiak; Alexander Ke 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB

Impact of high-risk cytogenetics and pri

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

✍ Avet-Loiseau, H; Soulier, J; Fermand, J-P; Yakoub-Agha, I; Attal, M; Hulin, C; G 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 313 KB